R&D

MVA-B Spanish HIV vaccine shows 90 percent immune response in humans

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Marañón Hospital in Madrid and Clínic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV). 90% of the volunteers who went through the tests developed an immunological response against the virus and 85% has kept this response for at least one year. Safety and efficiency of this treatment have been described in articles for Vaccine and Journal of Virology science magazines.

High Potential for the Immune and Antihypertensive Health Ingredients Market in Europe

The rising incidence of problems related to high blood pressure and weak immune system as well as the gravitation toward preventive healthcare is driving the European market for nutritional solutions in immune and antihypertensive health. The swine flu epidemic that hit Europe and the United States is one of the factors that boosted consumer interest in maintaining a healthy immune system.

ecancerHub - A New Approach to Cancer Communication

eurocancercoms has announced the launch of ecancerHub - a new, open-access, integrated approach to providing the whole cancer community - patients, doctors, researchers and policymakers - with high quality and trustworthy information. Integrating the best of social media technology into one unique platform, ecancerHub enables patients, healthcare professionals and researchers to interact, connect and share. They have the opportunity to discuss, debate, generate new ideas, gather opinions and build knowledge not only within their own groups, but also cross-community.

Innovative Medicines Initiative (IMI) 4th Call 2011

Based on the recommendations of the IMI Research Agenda, the IMI Governing Board has approved the IMI Annual Implementation Plan 2011, including the Scientific Priorities 2011. These priorities have been incorporated into the IMI 4th Call Topics. These priorities have been incorporated into the IMI 4th Call Topics. Applicants intending to submit an Expression of Interest (EoI) in response to the IMI 4th Call should read the Guide for Applicants, the Call Topics, the Rules for Participation, the Rules for Submission, Evaluation and Selection of EoIs and FPPs, the IMI IPR rules and the IMI JU model Grant Agreement.

VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression

VTU Technology, a leading contract research and development company providing services for the fast-track generation of high-performance industrial protein expression strains and processes for the biopharmaceutical and other protein industries announces the launch of their 2nd generation AOX1 promoter variants allowing for methanol-free protein expression in Pichia pastoris.

UCB launched Research Alliance with Harvard University

UCB and Harvard University officially launched their innovative Research Alliance during a signing ceremony in Boston in the presence of his Royal Highness Prince Philippe of Belgium. The Alliance creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway.

New Hope in Fight against the Flu

Pharmacelsus GmbH announced its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

Research & Development

MVA-B Spanish HIV vaccine shows 90 percent immune response in humans

High Potential for the Immune and Antihypertensive Health Ingredients Market in Europe

ecancerHub - A New Approach to Cancer Communication

Innovative Medicines Initiative (IMI) 4th Call 2011

VTU Technology Launches Breakthrough Technology for High Level Methanol-free Protein Expression

UCB launched Research Alliance with Harvard University

New Hope in Fight against the Flu

More Pharma News ...